New drug combo may boost stem cell success for rare bone marrow cancer
NCT ID NCT07471503
First seen Mar 15, 2026 · Last updated Apr 30, 2026 · Updated 10 times
Summary
This study tests whether the drug gecacitinib can help people with myelofibrosis (a serious bone marrow disease) who are getting a stem cell transplant. The goal is to reduce complications like graft-versus-host disease and relapse. About 39 adults aged 18-75 will take the drug before, during, and after transplant to see if it improves survival without major side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (MF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.